Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,187.47 -0.23 (-0.00%) Dow
39,032.11 +147.85 (+0.38%) Nasdaq
16,302.26 -30.30 (-0.19%) Bitcoin USD
62,605.64 -669.58 (-1.06%) CMC Crypto 200
1,327.95 +33.28 (+2.57%)
AXSM Dec 2024 105.000 call
| Previous close | 3.0700 |
| Open | 3.0700 |
| Bid | 2.9000 |
| Ask | 4.3000 |
| Strike | 105.00 |
| Expiry date | 2024-12-20 |
| Day's range | 3.0700 - 3.0700 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
GlobeNewswireAxsome Therapeutics to Present at Upcoming Investor Conferences
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in two upcoming investor conferences. The presentation details are as follows: RBC Capital Markets 2024 Global Healthcare Conference, on Tuesday, May 14, at 1:35 p.m. Eastern Time. Dr. Tabu
ZacksAxsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
Axsome's (AXSM) bottom line declines year over year in the first quarter. Strong sales of Auvelity drive revenues.
Insider MonkeyAxsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript May 6, 2024 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.44233 EPS, expectations were $-1.2. Axsome Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, […]
